title: Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
abstract: OBJECTIVE
  Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. The efficacy and safety of axitinib in Japanese patients with metastatic renal cell carcinoma were evaluated.
  
  
  METHODS
  A subgroup analysis was conducted in Japanese patients enrolled in the randomized Phase III trial of axitinib versus sorafenib after failure of one prior systemic therapy for metastatic renal cell carcinoma.
  
  
  RESULTS
  Twenty-five (of 361) and 29 (of 362) patients randomized to the axitinib and sorafenib arms, respectively, were Japanese and included in this analysis. Median progression-free survival in Japanese patients was 12.1 months (95% confidence interval 8.6 to not estimable) for axitinib and 4.9 months (95% confidence interval 2.8-6.6) for sorafenib (hazard ratio 0.390; 95% confidence interval 0.130-1.173; stratified one-sided P = 0.0401). The objective response rate was 52.0% for axitinib and 3.4% for sorafenib (P = 0.0001). The common all-causality adverse events (all grades) in Japanese patients were dysphonia (68%), hypertension (64%), hand-foot syndrome (64%) and diarrhea (56%) for axitinib, and hand-foot syndrome (86%), hypertension (62%) and diarrhea (52%) for sorafenib. The safety profiles of axitinib and sorafenib in Japanese patients were generally similar to those observed in the overall population, with the exceptions of higher incidences of hypertension, dysphonia, hand-foot syndrome, hypothyroidism and stomatitis.
  
  
  CONCLUSIONS
  Axitinib is efficacious and well tolerated in Japanese patients with previously treated metastatic renal cell carcinoma, consistent with the results in the overall population, providing a new targeted therapy for these Japanese patients.
authors: Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba-shi, Chiba 260-8717, Japan. urolccc@yahoo.co.jp
authors: Takeshi
authors: T
authors: Ueda
authors: Hirotsugu
authors: H
authors: Uemura
authors: Yoshihiko
authors: Y
authors: Tomita
authors: Taiji
authors: T
authors: Tsukamoto
authors: Hiroomi
authors: H
authors: Kanayama
authors: Nobuo
authors: N
authors: Shinohara
authors: Jamal
authors: J
authors: Tarazi
authors: Connie
authors: C
authors: Chen
authors: Sinil
authors: S
authors: Kim
authors: Seiichiro
authors: S
authors: Ozono
authors: Seiji
authors: S
authors: Naito
authors: Hideyuki
authors: H
authors: Akaza
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D005260:Female; D060831:Hand-Foot Syndrome / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007037:Hypothyroidism / Q000139:chemically induced; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011507:Proteinuria / Q000139:chemically induced; D000077157:Sorafenib; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007093:Imidazoles; D007191:Indazoles; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D000077784:Axitinib
keywords: axitinib; clinical trial; phase III; renal cell carcinoma; vascular endothelial growth factor receptors
references: Eval Health Prof. 2005 Jun;28(2):212-32
references: 15851774
references: Scand J Surg. 2004;93(2):88-96
references: 15285559
references: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references: 20100962
references: J Clin Oncol. 2009 Sep 20;27(27):4462-8
references: 19652060
references: Eur Urol. 2010 Feb;57(2):317-25
references: 19136199
references: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
references: 15674877
references: Eur J Cancer. 2011 Nov;47(17):2592-602
references: 21889330
references: Eur J Clin Pharmacol. 2012 May;68(5):645-55
references: 22170007
references: Clin Cancer Res. 2008 Nov 15;14(22):7272-83
references: 19010843
references: Drugs R D. 2011;11(2):113-26
references: 21679004
references: Lancet. 2007 Dec 22;370(9605):2103-11
references: 18156031
references: J Support Oncol. 2006 Apr;4(4):191-9
references: 16669463
references: Expert Rev Anticancer Ther. 2010 Oct;10(10):1545-57
references: 20942625
references: Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i51-56
references: 20870920
references: Clin Cancer Res. 2011 Dec 1;17(23):7462-9
references: 21976544
references: J Clin Oncol. 2009 Aug 10;27(23):3836-41
references: 19597027
references: Br J Cancer. 2008 Dec 2;99(11):1757-62
references: 18985035
references: Qual Life Res. 1996 Jun;5(3):309-20
references: 8763799
references: Curr Opin Investig Drugs. 2008 Jun;9(6):658-71
references: 18516765
references: J Urol. 2009 Oct;182(4):1271-9
references: 19683266
references: Value Health. 2005 Mar-Apr;8(2):94-104
references: 15804318
references: Eur J Cancer Prev. 2002 Apr;11(2):171-8
references: 11984136
references: Cancer Treat Rev. 2008 May;34(3):193-205
references: 18313224
references: Eur Urol. 2010 Sep;58(3):398-406
references: 20633979
references: Target Oncol. 2009 Dec;4(4):297-305
references: 19876699
references: Value Health. 2007 Jul-Aug;10(4):285-93
references: 17645683
references: J Clin Oncol. 2008 Oct 10;26(29):4708-13
references: 18541897
references: Cancer. 2010 Sep 15;116(18):4256-65
references: 20549832
references: Jpn J Clin Oncol. 2007 Oct;37(10):755-62
references: 17951335
references: Invest New Drugs. 2012 Jun;30(3):1055-64
references: 21301929
references: Int J Urol. 2010 Sep;17(9):811-5
references: 20649824
references: Cancer Chemother Pharmacol. 2010 Feb;65(3):563-70
references: 19603168
references: Cancer Sci. 2010 Apr;101(4):963-8
references: 20180805
references: Int J Urol. 2012 Jun;19(6):496-503
references: 22621218
references: Lancet. 2008 Aug 9;372(9637):449-56
references: 18653228
references: N Engl J Med. 2007 May 31;356(22):2271-81
references: 17538086
references: Lancet Oncol. 2007 Nov;8(11):975-84
references: 17959415
references: Lancet. 2011 Dec 3;378(9807):1931-9
references: 22056247
references: N Engl J Med. 2007 Jan 11;356(2):125-34
references: 17215530
references: J Urol. 2008 May;179(5):1704-8
references: 18343443
references: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references: 19487381
references: Int J Urol. 2007 Jun;14(6):479-82
references: 17593088